Table 1 Baseline, demographic and disease-related parameters in childhood-onset Takayasu arteritis (c-TA) and healthy control group (CTRL).
c-TA (n = 17) | CTRL (n = 17) | |
|---|---|---|
Demographic parameters | ||
Age (years) | 18.4 (19) ± 3.44 (12–20) | 18.5 (20) ± 3.50 (12–21) |
Sex, female, n (%) | 11 (64.7) | 11 (64.7) |
Height (m) | 1.60 (1.57) ± 0.11 (1.46–1.64) | 1.65 (1.62) ± 0.12 (1.40–1.74) |
Body weight (kg) | 56.1 (54.8) ± 10.6 (40.6–63.8) | 60.6 (62.0) ± 13.3 (31.2–71.0) |
BMI (kg/m2) | 17.4 (17.3) ± 2.68 (13.4–18.8) | 18.2 (18.5) ± 3.39 (11.0-20.4) |
Disease duration (years) | 9.48 (10.1) ± 4.16 (7.07–11.8) | NA |
Age at the disease onset (years) | 9.25 (9.50) ± 4.62 (6.75-13.0) | NA |
TA classification n, (%) | ||
Type I | 1 (5.88) | NA |
Type IIa | 1 (5.88) | NA |
Type III | 2 (11.7) | NA |
Type IV | 4 (23.5) | NA |
Type V | 9 (52.9) | NA |
Arterial hypertension, n (%) | 10 (58.8) | NA |
Aortic stenosis, n (%) | 9 (52.9) | NA |
Biological therapy, n (%) | ||
Infliximab | 5 (29.4) | NA |
Non-biological therapy, n (%) | ||
Methotrexate | 8 (47.0) | NA |
Leflunomide | 5 (29.4) | NA |
Prednisone | 4 (23.5) | NA |
Enalapril | 5 (29.4) | NA |
Amlodipine | 3 (17.2) | NA |
Disease score | ||
ITAS score | 0.0 (0.0–0.0) | NA |
PVAS score | 0.0 (0.0–1.0) | NA |